Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial

Yee Wen Kong; Cheng Yi Yuan; Katerina Kiburg; Katrin Brown; Steven Trawley; Andi Partovi; Kerryn Roem; Cecilia Pham; Natalie Harrison; Spiros Fourlanos; Elif I. Ekinci; David N. O’Neal

doi:10.1210/clinem/dgae088

Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial

Yee Wen Kong
, Cheng Yi Yuan
, Katerina Kiburg
, Katrin Brown
, Steven Trawley
, Andi Partovi
, Kerryn Roem
, Cecilia Pham
, Natalie Harrison
, Spiros Fourlanos
, Elif I. Ekinci
, David N. O’Neal

Research output: Contribution to journal › Article › Research › peer-review

5 Citations (Scopus)

Abstract

Context: Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed insulin pump therapy (IPT). Objective: We compared treatment satisfaction with Omnipod DASH System to usual care (multiple daily injections [MDIs] or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG). Methods: Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from 4 diabetes centers in Australia were randomly assigned in a 1:1 nonblinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension during which all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire “current” (ΔDTQ-current) score at 12 weeks (study end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, and glycemic and device-related outcomes at 12 weeks (study end) and 24 weeks (end extension). Results: Treatment satisfaction improved more in the Omnipod group vs the Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001) at study end. Significantly greater improvements in other PROs and glycated hemoglobin A_1c were also observed. Improvements in DTQ-current and other PROs comparing study end and end extension were similar. While percentage in time in range change from baseline did not differ at study end (−2.0 [12.7] %), it was significantly greater at end extension (5.6 [10.9] %; P = .016). Conclusion: The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.

Original language	English
Pages (from-to)	1984-1995
Number of pages	12
Journal	The Journal of Clinical Endocrinology & Metabolism
Volume	109
Issue number	8
DOIs	https://doi.org/10.1210/clinem/dgae088
Publication status	Published - 1 Aug 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Omnipod DASH system
quality of life
treatment satisfaction
tubeless insulin pump therapy

Access to Document

10.1210/clinem/dgae088Licence: CC BY-NC-ND

Cite this

Kong, Y. W., Yuan, C. Y., Kiburg, K., Brown, K., Trawley, S., Partovi, A., Roem, K., Pham, C., Harrison, N., Fourlanos, S., Ekinci, E. I., & O’Neal, D. N. (2024). Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 109(8), 1984-1995. https://doi.org/10.1210/clinem/dgae088

@article{596111c19fc5476399c8f55257c0d179,

title = "Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial",

abstract = "Context: Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed insulin pump therapy (IPT). Objective: We compared treatment satisfaction with Omnipod DASH System to usual care (multiple daily injections [MDIs] or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG). Methods: Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from 4 diabetes centers in Australia were randomly assigned in a 1:1 nonblinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension during which all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire “current” (ΔDTQ-current) score at 12 weeks (study end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, and glycemic and device-related outcomes at 12 weeks (study end) and 24 weeks (end extension). Results: Treatment satisfaction improved more in the Omnipod group vs the Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001) at study end. Significantly greater improvements in other PROs and glycated hemoglobin A1c were also observed. Improvements in DTQ-current and other PROs comparing study end and end extension were similar. While percentage in time in range change from baseline did not differ at study end (−2.0 [12.7] \%), it was significantly greater at end extension (5.6 [10.9] \%; P = .016). Conclusion: The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.",

keywords = "Omnipod DASH system, quality of life, treatment satisfaction, tubeless insulin pump therapy",

author = "Kong, \{Yee Wen\} and Yuan, \{Cheng Yi\} and Katerina Kiburg and Katrin Brown and Steven Trawley and Andi Partovi and Kerryn Roem and Cecilia Pham and Natalie Harrison and Spiros Fourlanos and Ekinci, \{Elif I.\} and O{\textquoteright}Neal, \{David N.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.",

year = "2024",

month = aug,

day = "1",

doi = "10.1210/clinem/dgae088",

language = "English",

volume = "109",

pages = "1984--1995",

journal = "The Journal of Clinical Endocrinology \& Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press, USA",

number = "8",

}

Kong, YW, Yuan, CY, Kiburg, K, Brown, K, Trawley, S, Partovi, A, Roem, K, Pham, C, Harrison, N, Fourlanos, S, Ekinci, EI & O’Neal, DN 2024, 'Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial', The Journal of Clinical Endocrinology & Metabolism, vol. 109, no. 8, pp. 1984-1995. https://doi.org/10.1210/clinem/dgae088

TY - JOUR

T1 - Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes

T2 - A Nonblinded 1:1 Randomized Controlled Trial

AU - Kong, Yee Wen

AU - Yuan, Cheng Yi

AU - Kiburg, Katerina

AU - Brown, Katrin

AU - Trawley, Steven

AU - Partovi, Andi

AU - Roem, Kerryn

AU - Pham, Cecilia

AU - Harrison, Natalie

AU - Fourlanos, Spiros

AU - Ekinci, Elif I.

AU - O’Neal, David N.

PY - 2024/8/1

Y1 - 2024/8/1

N2 - Context: Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed insulin pump therapy (IPT). Objective: We compared treatment satisfaction with Omnipod DASH System to usual care (multiple daily injections [MDIs] or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG). Methods: Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from 4 diabetes centers in Australia were randomly assigned in a 1:1 nonblinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension during which all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire “current” (ΔDTQ-current) score at 12 weeks (study end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, and glycemic and device-related outcomes at 12 weeks (study end) and 24 weeks (end extension). Results: Treatment satisfaction improved more in the Omnipod group vs the Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001) at study end. Significantly greater improvements in other PROs and glycated hemoglobin A1c were also observed. Improvements in DTQ-current and other PROs comparing study end and end extension were similar. While percentage in time in range change from baseline did not differ at study end (−2.0 [12.7] %), it was significantly greater at end extension (5.6 [10.9] %; P = .016). Conclusion: The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.

AB - Context: Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed insulin pump therapy (IPT). Objective: We compared treatment satisfaction with Omnipod DASH System to usual care (multiple daily injections [MDIs] or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG). Methods: Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from 4 diabetes centers in Australia were randomly assigned in a 1:1 nonblinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension during which all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire “current” (ΔDTQ-current) score at 12 weeks (study end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, and glycemic and device-related outcomes at 12 weeks (study end) and 24 weeks (end extension). Results: Treatment satisfaction improved more in the Omnipod group vs the Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001) at study end. Significantly greater improvements in other PROs and glycated hemoglobin A1c were also observed. Improvements in DTQ-current and other PROs comparing study end and end extension were similar. While percentage in time in range change from baseline did not differ at study end (−2.0 [12.7] %), it was significantly greater at end extension (5.6 [10.9] %; P = .016). Conclusion: The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.

KW - Omnipod DASH system

KW - quality of life

KW - treatment satisfaction

KW - tubeless insulin pump therapy

UR - https://www.scopus.com/pages/publications/85198667665

U2 - 10.1210/clinem/dgae088

DO - 10.1210/clinem/dgae088

M3 - Article

C2 - 38373265

AN - SCOPUS:85198667665

SN - 0021-972X

VL - 109

SP - 1984

EP - 1995

JO - The Journal of Clinical Endocrinology & Metabolism

JF - The Journal of Clinical Endocrinology & Metabolism

IS - 8

ER -

Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this